Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James) are advancing the understanding of a promising blood test that could personalize treatment and surveillance for patients with human papillomavirus (HPV)-associated throat cancer. The research, published in JAMA Otolaryngology—Head and Neck Surgery, explores how a blood-based test, circulating tumor HPV DNA (ctDNA), changes before and after surgery. The study explores how tumor biology and patient factors influence ctDNA levels. The findings provide important new insight into how this ctDNA test can be used along with pathology reports to improve risk assessment and personalize treatment plans.
This article was originally published on MedicalXpress.com
